Results 71 to 80 of about 655,147 (306)

Rivaroxaban: A New Oral Factor Xa Inhibitor [PDF]

Arteriosclerosis, Thrombosis, and Vascular Biology, 2010
Rivaroxaban is a direct inhibitor of factor Xa, a coagulation factor at a critical juncture in the blood coagulation pathway leading to thrombin generation and clot formation. It is selective for human factor Xa, for which it has >10 000-fold greater selectivity than for other biologically relevant serine proteases (half-maximal ...
Elisabeth, Perzborn, Susanne, Roehrig, Alexander, Straub, Dagmar, Kubitza, Wolfgang, Mueck, Volker, Laux   +5 more
openaire   +2 more sources

Direct oral anticoagulant blood level monitoring in daily practice

Thrombosis Update, 2021
Introduction: Routine monitoring is not required in direct oral anticoagulant (DOAC) treatment, yet it is frequently performed. Guidance on the interpretation and management of DOAC level measurements is lacking and it is key to investigate which ...
R. Bavalia, J.E. Veenhuizen, R.C.C. Hengeveld, D. Braeken, A.J.W. Gulpen, H. Ten Cate, S. Middeldorp, Y.M.C. Henskens, B.A. Hutten, M. Coppens, A.K. Stroobants   +10 more
doaj   +1 more source

Modeling of interstitial branching of axonal networks [PDF]

, 2013
A single axon can generate branches connecting with plenty synaptic targets. Process of branching is very important for making connections in central nervous system.
Gafarov, F., Khusnutdinov, N., Suleymanov, Y.   +2 more
core   +2 more sources

Preconditioning of mesenchymal stromal cells with low-intensity ultrasound: influence on chondrogenesis and directed SOX9 signaling pathways [PDF]

, 2020
Background: Continuous low-intensity ultrasound (cLIUS) facilitates the chondrogenic differentiation of human mesenchymal stromal cells (MSCs) in the absence of exogenously added transforming growth factor-beta (TGFβ) by upregulating the expression of ...
A Argentaro, A Augello, A Katsumi, A Woods, A Woods, AD Miller, AH Huang, B Yang, BH Choi, C Huang, C Matta, CA Simmons, CB Little, CJ O’Conor, CY Huang, D Schumann, DR Haudenschild, EM Darling, F Dell'Accio, G Coricor, H Sim, H-C Hsu, HJ Kwon, HJ Lee, HJ Lee, J Li, J Puetzer, JC Sng, JD Kisiday, JH Cui, JH Cui, JW Choi, K Ebisawa, K Pelttari, L Bian, Li Ling, LJ Ng, M Shakibaei, M Tsuda, MA Corrigan, MB Mueller, N Fahy, N Thelin, NP Whitney, P Müller, R Ogawa, RL Mauck, RM Delaine-Smith, RS Tigli, S Murakami, S Noriega, S Noriega, S Yamaguchi, SD Cook, SD Cook, T Furumatsu, T Guo, T Ito, T Juhasz, T Nishida, T Sanjukta Guha, TM Louw, V Lefebvre, V Lefebvre, W Huang, W Huang, Z Li, ZJ Zhang   +67 more
core   +2 more sources

Factor Xa Inhibitors Versus Vitamin K Antagonists for Prevention of Cerebral or Systemic Embolism in Patients With Atrial Fibrillation

Cochrane Database of Systematic Reviews, 2018
BACKGROUND Factor Xa inhibitors and vitamin K antagonists (VKAs) are now recommended in treatment guidelines for preventing stroke and systemic embolic events in people with atrial fibrillation (AF).
K. B. Bruins Slot, E. Berge
semanticscholar   +1 more source

Fermented Lacticaseibacillus Paracasei Cultures Ameliorate Colitis by Modulating Microbiota‐Derived Tryptophan Metabolism and Macrophage Polarization

Advanced Science, EarlyView.
A solid‐state fermented probiotic (PYW) is developed using wheat bran as substrate, containing high viable Lacticaseibacillus paracasei and bioactive metabolites. PYW alleviates intestinal inflammation by gut microbiota composition, enriching indole derivatives, activating aryl hydrocarbon receptor signaling, and regulating macrophage polarization. PYW
Heng Zhang, Jingzhou Sun, Xin Zheng, Huiqing Yang, Aowen Xie, Yuxuan Ding, Yuxia Mei, Jinshan Li, Yuanliang Hu, Min Ren, Yangyang Liu, Yunxiang Liang   +11 more
wiley   +1 more source

Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation

TH Open, 2018
Rivaroxaban and apixaban are both small molecules that reversibly inhibit factor Xa. Compared with rivaroxaban, apixaban has minimal effects on the prothrombin time and activated partial thromboplastin time.
Paul Y. Kim, Calvin H. Yeh, Brian J. Dale, Beverly A. Leslie, Alan R. Stafford, James C. Fredenburgh, Jack Hirsh, Jeffrey I. Weitz   +7 more
doaj   +1 more source

New Hybrid Tetrahydropyrrolo[3,2,1-ij]quinolin-1-ylidene-2-thioxothiazolidin-4-ones as New Inhibitors of Factor Xa and Factor XIa: Design, Synthesis, and In Silico and Experimental Evaluation

Molecules, 2023
Despite extensive research in the field of thrombotic diseases, the prevention of blood clots remains an important area of study. Therefore, the development of new anticoagulant drugs with better therapeutic profiles and fewer side effects to combat ...
Nadezhda P. Novichikhina, Alexander S. Shestakov, Svetlana M. Medvedeva, Anna M. Lagutina, Mikhail Yu. Krysin, Nadezhda A. Podoplelova, Mikhail A. Panteleev, Ivan S. Ilin, Alexey V. Sulimov, Anna S. Tashchilova, Vladimir B. Sulimov, Athina Geronikaki, Khidmet S. Shikhaliev   +12 more
doaj   +1 more source

Antiagregación y anticoagulación en síndromes coronarios agudos: niveles de evidencia [PDF]

, 2007
Management of acute coronary syndromes (ACS) has moved rapidly in parallel with our understanding of the pathophysiological basis of the disease. In the eighties, the demonstration of the pivotal role of coronary thrombosis in the etiology of a ACS led ...
Garcia, R. (R.), Paramo, J.A. (José Antonio), Rodriguez, P. (P.), Ruiz-de-Gaona, E. (Estefanía)   +3 more
core  

Plasmin Regulation through Allosteric, Sulfated, Small Molecules [PDF]

, 2015
Plasmin, a key serine protease, plays a major role in clot lysis and extracellular matrix remodeling. Heparin, a natural polydisperse sulfated glycosaminoglycan, is known to allosterically modulate plasmin activity.
Al-Horani, Rami A., Desai, Umesh R., Karuturi, Rajesh, White, Domonique T.   +3 more
core   +3 more sources